Diacrin Inc. of Charlestown, Mass., has hired E. Michael Egan tobe its senior vice president of corporate development. Eganjoins Diacrin from Repligen Corp., where he was vice presidentof business development.
R. Bruce Reeves has been named chief executive officer andpresident of Biorelease Corp. Reeves had been with the Salem,N.H., company since 1989, most recently as executive vicepresident, chief operating officer and secretary. He had alsobeen the president of the company's operating subsidiary,Biorelease Technologies Inc.
Liposome Technology Inc. of Menlo Park, Calif., has appointedGeorge Francis Tidmarsh as associate medical director,oncology, to oversee the clinical development of Doxil.Tidmarsh had been a research scientist at Gilead Sciences aswell as an oncology/hematology fellow at Lucile Salter PackardChildren's Hospital at Stanford University.
Larry Soll, chief executive and chairman of the board ofSynergen Inc., now holds a seat on ImmuLogic PharmaceuticalCorp.'s board of directors. Soll replaces James Bochnowski ofDelphi Bioventures, which was an initial venture capitalinvestor in ImmuLogic of Waltham, Mass.
Vincent Anido Jr. is the new president of the Americas regionof Allergan Inc., based in Irvine, Calif. Anido will beresponsible for sales and marketing of Allergan products inthe U.S., Canada and Latin America. He had been the vicepresident of business management for Marion Merrell DowInc.'s U.S. prescription products division.
Neose Pharmaceuticals Inc. of Horsham, Pa. has hired DavidPritchard as vice president of business development andRobert Fleming as director of manufacturing and operations.Pritchard had been the director of corporate development atMolecular Biosystems Inc. Fleming brings to Neosepharmaceutical manufacturing experience at Vestar Inc., AdriaLaboratories and the Mead-Johnson division of Bristol-Myers.
Neose also appointed two new board members: DouglasMacMaster, recently retired from Merck & Co., where he wassenior vice president for worldwide chemical andpharmaceutical manufacturing and Jerry Weisbach, who, beforehis retirement, had been the president of Warner-Lambert Co.'spharmaceutical division.
(c) 1997 American Health Consultants. All rights reserved.